RxDoctor Payments Data

Abel Rivero, MD

Interventional Cardiology · The Villages, FLNPI 1659531937

Payments from drug & device makers

$10,893in general payments, 2019–2025

Across 404 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$2K
  • Penumbra, Inc.$2K
  • Alnylam Pharmaceuticals Inc.$583
  • Pfizer$570
  • Medtronic$564
  • Novartis$546
  • plus $5K from 43 others

What the payments were for

  • Travel & lodging$2,67125%
  • Food & beverage$8,03874%
  • Education$1451%
  • Other$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,893 in reported general payments places this provider in the 50th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$798,433
Medicare patients
1,232
Services billed
8,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban742$965,908
VyndamaxTafamidis14$440,729
Repatha SureclickEvolocumab322$369,931
VyndaqelTafamidis Meglumine12$290,226
MultaqDronedarone Hcl75$115,715
XareltoRivaroxaban75$113,030
EntrestoSacubitril/Valsartan73$112,738
Praluent PenAlirocumab59$56,054
FarxigaDapagliflozin Propanediol37$37,438
VascepaIcosapent Ethyl55$35,300
BrilintaTicagrelor36$34,686
NexletolBempedoic Acid36$28,618
JardianceEmpagliflozin16$23,749
Repatha SyringeEvolocumab13$18,312
Rosuvastatin Calcium895$14,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax, Vyndaqel$570$1,696,863768 claims
Sanofi-aventis U.S. LLCMultaq$278$115,71575 claims
Johnson & JohnsonXarelto$207$113,03075 claims
NovartisEntresto$546$112,73873 claims
AstraZenecaFarxiga, Brilinta$311$72,12373 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$157$38,44849 claims
Boehringer IngelheimJardiance$101$23,74916 claims
Kowa Pharmaceuticals America, Inc.Livalo$50$12,02619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →